Page 1

Table of Contents ( Mark One ) ☐ ☑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20 - F REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 ☐ For the transition period from to OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number : 001-36815 Ascendis Pharma A / S ( Exact name of Registrant as specified in its charter and translation of Registrant's name into English ) The Kingdom of Denmark ( Jurisdiction of incorporation or organization ) Tuborg Boulevard 12 DK - 2900 Hellerup , Denmark ( Address of principal executive offices ) Jan Møller Mikkelsen President and Chief Executive Officer Tuborg Boulevard 12 DK - 2900 Hellerup , Denmark Telephone : +45 70 22 22 44 ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ASND Name of each exchange on which registered The Nasdaq Stock Market LLC Title of each class American Depositary Shares , each representing one ordinary share , nominal value DKK 1 per share Ordinary shares , nominal value DKK 1 per share * The Nasdaq Stock Market LLC *